Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment.

ABSTRACT: Targeted radionuclide therapy (TRT) and immunotherapy are rapidly growing classes of cancer treatments. Basic, translational, and clinical research are now investigating therapeutic combinations of these agents. In comparison to external beam radiation therapy (EBRT), TRT has the unique advantage of treating all disease sites following intravenous injection and selective tumor uptake and retention-a particularly beneficial property in metastatic disease settings. The therapeutic value of combining radiation therapy with immune checkpoint blockade to treat metastases has been demonstrated in preclinical studies, whereas results of clinical studies have been mixed. Several clinical trials combining TRT and immune checkpoint blockade have been initiated based on preclinical studies combining

SUBMITTER: Kerr CP 

PROVIDER: S-EPMC9865370 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature